Holdout Celera shareholder sells stock to Quest Diagnostics

A large hedge fund investor in Celera Corp. surrendered its 19.3 million shares to Quest Diagnostics Inc. , which bought the Alameda genetic test developer in May.
Biotechnology Value Fund LP withdrew its demand for an appraisal of its shares and accepted the same $8-per-share payout Quest (NYSE: DGX) made to other Celera shareholders. BVF general partner Mark Lampert had said in March that the Quest deal didn't adequately value Celera.

To move along $344M Quest deal, Celera plans to settle 4 shareholder suits

Celera Corp. will settle four shareholder lawsuits filed after Quest Diagnostics Inc. said it would buy the Alameda medical test developer for $344 million.
Meanwhile, Celera and Quest (NYSE: DGX) agreed to lower the deal’s termination fee to $15.6 million from $23.45 million, and Quest said it will extend its $8 per share offer until 5 p.m. (Eastern time) on May 2.

Big Celera shareholders line up against Quest deal

Two Celera Corp. shareholders do not support the company’s planned $344 million acquisition by Quest Diagnostics Inc. and say the companies need to renegotiate the deal.
Starboard Value & Opportunity Fund and Biotechnology Value Fund LP said in separate letters to Alameda-based genetic test developer Celera (NASDAQ: CRA) and Quest (NYSE: DGX) that the $8 per share deal does not reflect Celera’s value.

Celera sells for $344M to Quest Diagnostics

Alameda-based Celera Corp., a maker of genetic tests, was purchased by New Jersey-based Quest Diagnostics Inc. in a deal valued at $344 million.
Quest will pay $8 per share of Celera, which reported revenue of $128 million in 2010.
Celera executives said the company had been looking for a partner for sometime to help market and sell its testing products.